Paper Review Records
All Paper Review Records
20 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
206
days
Decoding glioblastoma evolution and heterogeneity through mechanistic modeling: implications for clinical translation
Authors
Haowu Jiang; Wan Zhao; Hui Zhou; Rui SunShow moreShow less
Affiliations
1. Department of Otolaryngology-Head and Neck Surgery, The First Affiliated Hospital of USTC, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Hefei National Research Center for Physical Sciences at the Microscale, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, People’s Republic of China; 2. Department of Otolaryngology-Head and Neck Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, People’s Republic of China; 3. Department of Respiratory Medicine, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China (Anhui Provincial Cancer Hospital), Hefei, People’s Republic of China; 4. Department of Immunology, School of Basic Medical Sciences, Anhui Medical University, Hefei, People’s Republic of ChinaShow moreShow less
160
days
From paradox to target: IFN-β hijacks MEK signaling to drive a cell death-evading dormant phenotype in colorectal cancer
Authors
Yangyang Zhou; Haigang Geng; Yi Xu; Yanggang Hong; Bo Mei; Huanglei Wu; Xuanxuan Jin; Mengfan Ye; Yi Wang; Zan Shen; Zhigang Zheng; Zhenhua Zhu; Xiangchou Yang; Zizhen Zhang; Chunchao ZhuShow moreShow less
Affiliations
1. Department of Oncology, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China; 2. Department of Gastrointestinal Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; 3. Department of Gastrointestinal Cancer Translational Research, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital, Beijing, China; 4. State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; 5. The Second School of Medicine, Wenzhou Medical University, Wenzhou, China; 6. Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Key Laboratory of Research, Investigation and Evaluation of Radiopharmaceuticals, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Beijing, China; 7. Department of Coloprotology, The Second Affiliated Hospital & Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, China; 8. Department of Urology, The Second Affiliated Hospital & Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, China; 9. The First School of Medicine, School of Information and Engineering, Wenzhou Medical University, Wenzhou, China; 10. Shanghai Cancer Institute, State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; 11. Department of Pathophysiology, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine, Shanghai, China; 12. Department of Hematology and Medical Oncology, The Second Affiliated Hospital & Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, ChinaShow moreShow less
206
days
HES1 inhibition overcomes CDK4/6 inhibitor resistance by targeting cancer stemness in lung adenocarcinoma
Authors
Alvin Ho Kwan Cheung; Kit Yee Wong; Gordon Yuan-Ho Li; Fuda Xie; Qiuqiu Wu; Thomas Tin Ho Yuen; Pak Lam Hui; Pingmei Huang; Xiaoli Liu; Bonan Chen; Fenfen Ji; Yujuan Dong; Alfred Sze-Lok Cheng; Calvin Sze Hang Ng; Xiang Zhang; Chi Chun Wong; Jun Yu; Wei Kang; Ka-Fai ToShow moreShow less
Affiliations
1. Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, China; 2. Department of Medicine and Therapeutics, Institute of Digestive Disease, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China; 3. Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, China; 4. School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong SAR, ChinaShow moreShow less
32
days
Targeting metabolic dependencies to reverse chemoradiotherapy resistance in colorectal cancer
Authors
Maximilian Hellkamp; Simon Gertken; Jonas Buchloh; Julius-Leonard Hellwig; Lukas Ben Kowitzke; Ningjun Duan; Ilaria Gaspardo; Stefan Küffer; Michael Linnebacher; Philipp Ströbel; Matthias Wirth; Volker Ellenrieder; Stefan Rieken; Jochen Gaedcke; Michael Ghadimi; Jürgen Wienands; Günter Schneider; Melanie Spitzner; Marian GradeShow moreShow less
Affiliations
1. Department of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Göttingen, Germany; 2. Research Training Group (RTG) 2978, University Medical Center Göttingen, Göttingen, Germany; 3. Institute of Pathology, University Medical Center Göttingen, Göttingen, Germany; 4. Molecular Oncology and Immunotherapy, Clinic of General Surgery, University Medical Center Rostock, Rostock, Germany; 5. CCC-N (Comprehensive Cancer Center Lower Saxony), Göttingen, Germany; 6. Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; 7. Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Göttingen, Germany; 8. Department of Radiotherapy and Radiooncology, University Medical Center Göttingen, Göttingen, Germany; 9. Clinic for General and Visceral Surgery, Städtisches Klinikum Karlsruhe, Karlsruhe, Germany; 10. Institute of Cellular and Molecular Immunology, University Medical Center Göttingen, Göttingen, Germany; 11. Institute for Translational Cancer Research and Experimental Cancer Therapy, Technical University Munich, Munich, GermanyShow moreShow less
128
days
Cellular immunotherapy in melanoma: the next frontier in cancer treatment
Authors
Anna-Lena Wien; Angeliki Stamtsis-DatsiShow moreShow less
Affiliations
1. Institute for Transplantation Diagnostics and Cell Therapeutics, Medical Faculty, University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Düsseldorf, GermanyShow moreShow less
108
days
Loss of CSE couples with BRAF V600E to fuel thyroid cancer metastatic progression through zinc-dependent activation of the EMT machinery
Authors
Shichen Xu; Huixin Yu; Hongxun Wu; Zongfu Pan; Jiajie Xu; Yun Zhu; Botao Huang; Gangming Cai; Xiaobo Gu; Min Yang; Donghui Pan; Jie Pan; Jing Wu; Xian Cheng; Jiandong Bao; Li ZhangShow moreShow less
Affiliations
1. National Health Commission Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, China; 2. Jiangsu Institute of Nuclear Medicine Jiangyuan Hospital of Jiangsu Province, Wuxi, China; 3. Department of Pharmacy, Center for Clinical Pharmacy, Cancer Center, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical College, Hangzhou, China; 4. Department of Head and Neck Surgery, Otolaryngology & Head and Neck Center, Cancer Center, Zhejiang Provincial People’s Hospital, Hangzhou, China; 5. Department of Radiopharmaceuticals, School of Pharmacy, Nanjing Medical University, Nanjing, China; 6. School of Life Sciences, Nanjing Medical University, Changzhou, China; 7. School of Life science and Technology, Southeast University, Nanjing, ChinaShow moreShow less
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review62 days
Median65 days